Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.81 |
| ▸ | CTSD | P07339 | 5/20 | 0.68 |
| ▸ | CTSE | P14091 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878685 | 0.89 | BACE1 (0.83) | BACE1CTSDCTSE | |
| Hydrochloric Acid SCHEMBL4871349 | 0.89 | BACE1 (0.99) | BACE1CTSDCTSE | |
| SCHEMBL4878576 | 0.88 | BACE1 (0.79) | BACE1CTSDCTSE | |
| SCHEMBL4881174 | 0.88 | BACE1 (0.81) | BACE1CTSDCTSE | |
| SCHEMBL3969588 | 0.88 | BACE1 (0.79) | BACE1CTSDCTSE | |
| SCHEMBL4873213 | 0.88 | BACE1 (0.79) | BACE1CTSDCTSE | |
| SCHEMBL4872636 | 0.88 | BACE1 (0.80) | BACE1CTSDCTSE | |
| SCHEMBL4872973 | 0.86 | BACE1 (0.78) | BACE1CTSDCTSE | |
| SCHEMBL4872702 | 0.86 | BACE1 (0.86) | BACE1CTSDCTSE | |
| SCHEMBL4878643 | 0.86 | BACE1 (0.77) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 14/4885CTSE 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.